Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model

<div>CKD-MBD-related serologic markers in patients with CKD at stage 5. Target levels: calcium, 8.4 to 9.6 mg/dL; phosphate, 2.4 to 5.0 mg/dL; Ca×P product, &lt;55 mg<sup>2</sup>/dL<sup>2</sup>; and iPTH, 100 to 300 pg/mL. Abbreviations: CKD-MBD: chronic kidney disease-mineral bone disorder; iPTH: intact parathyroid hormone.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model 

Figure 4 | Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model 